Published in AIDS on June 13, 2003
Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy | NCT00307164
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS (2009) 2.91
Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab (2007) 1.97
Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis (2008) 1.81
Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 1.70
Adipocyte, adipose tissue, and infectious disease. Infect Immun (2006) 1.36
HIV and HAART-Associated Dyslipidemia. Open Cardiovasc Med J (2011) 1.34
Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection. Antivir Ther (2008) 1.05
Mitochondrial oxidative phosphorylation protein levels in peripheral blood mononuclear cells correlate with levels in subcutaneous adipose tissue within samples differing by HIV and lipoatrophy status. AIDS Res Hum Retroviruses (2008) 0.95
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors. Antimicrob Agents Chemother (2009) 0.95
Comparison of dorsocervical with abdominal subcutaneous adipose tissue in patients with and without antiretroviral therapy-associated lipodystrophy. Diabetes (2011) 0.94
Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors. J Acquir Immune Defic Syndr (2012) 0.94
Body composition and metabolic changes in HIV-infected patients. J Infect Dis (2012) 0.92
HIV infection and antiretroviral therapy have divergent effects on mitochondria in adipose tissue. J Infect Dis (2012) 0.92
Adipose tissue and immune function: a review of evidence relevant to HIV infection. J Infect Dis (2013) 0.91
Mitochondrial DNA content, an inaccurate biomarker of mitochondrial alteration in human immunodeficiency virus-related lipodystrophy. Antimicrob Agents Chemother (2008) 0.89
Zidovudine and Lamivudine for HIV Infection. Clin Med Rev Ther (2010) 0.89
Genes linked to energy metabolism and immunoregulatory mechanisms are associated with subcutaneous adipose tissue distribution in HIV-infected men. Pharmacogenet Genomics (2011) 0.88
LMNA mutations induce a non-inflammatory fibrosis and a brown fat-like dystrophy of enlarged cervical adipose tissue. Am J Pathol (2011) 0.87
Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229. AIDS (2010) 0.86
The kinetic effects on thymidine kinase 2 by enzyme-bound dTTP may explain the mitochondrial side effects of antiviral thymidine analogs. Antimicrob Agents Chemother (2011) 0.85
Zidovudine impairs adipogenic differentiation through inhibition of clonal expansion. Antimicrob Agents Chemother (2008) 0.85
Impact of lipoatrophy on quality of life in HIV patients receiving anti-retroviral therapy. AIDS Care (2008) 0.85
Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices. Eur J Clin Nutr (2007) 0.84
Role of mitochondria in HIV infection and associated metabolic disorders: focus on nonalcoholic fatty liver disease and lipodystrophy syndrome. Oxid Med Cell Longev (2013) 0.83
Is oxygen a key factor in the lipodystrophy phenotype? Lipids Health Dis (2006) 0.83
The role of HIV and monocytes/macrophages in adipose tissue biology. J Acquir Immune Defic Syndr (2014) 0.83
Thymidine kinase 2 deficiency-induced mitochondrial DNA depletion causes abnormal development of adipose tissues and adipokine levels in mice. PLoS One (2011) 0.83
Site-specific reduction of oxidative and lipid metabolism in adipose tissue of 3'-azido-3'-deoxythymidine-treated rats. Antimicrob Agents Chemother (2006) 0.82
Quality assessment of human mitochondrial DNA quantification: MITONAUTS, an international multicentre survey. Mitochondrion (2011) 0.82
Toxicity associated with stavudine dose reduction from 40 to 30 mg in first-line antiretroviral therapy. PLoS One (2011) 0.82
Fatigue-related gene networks identified in CD(14)+ cells isolated from HIV-infected patients: part I: research findings. Biol Res Nurs (2013) 0.81
Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: Alteration of the PPARγ-dependent pathways. PPAR Res (2008) 0.81
Aging of the human innate immune system in HIV infection. Curr Opin Immunol (2014) 0.81
Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir. Antivir Ther (2011) 0.81
The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patients. PPAR Res (2008) 0.80
Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy. Pharmacogenomics (2009) 0.78
Thymidine analogues suppress autophagy and adipogenesis in cultured adipocytes. Antimicrob Agents Chemother (2012) 0.78
High-dose clevudine impairs mitochondrial function and glucose-stimulated insulin secretion in INS-1E cells. BMC Gastroenterol (2012) 0.78
Epidemiology and management of antiretroviral-associated cardiovascular disease. Open AIDS J (2015) 0.78
Prevalence of and Risk Factors for Lipoatrophy in Patients with HIV Infection in Nigeria. AIDS Res Treat (2015) 0.77
Differential subcutaneous adipose tissue gene expression patterns in a randomized clinical trial of efavirenz or lopinavir-ritonavir in antiretroviral-naive patients. Antimicrob Agents Chemother (2014) 0.76
PharmGKB summary: zidovudine pathway. Pharmacogenet Genomics (2012) 0.76
Adipose Tissue in HIV Infection. Compr Physiol (2017) 0.75
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature (2004) 9.53
Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science (2007) 4.60
Adaptation of HIV-1 to human leukocyte antigen class I. Nature (2009) 4.24
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med (2005) 3.68
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol (2005) 3.23
Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis (2006) 2.40
HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J Immunol (2005) 2.24
HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One (2009) 2.16
Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A (2004) 2.15
Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol (2007) 2.10
Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol (2006) 1.99
Prevalence of war-related sexual violence and other human rights abuses among internally displaced persons in Sierra Leone. JAMA (2002) 1.97
Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A (2012) 1.89
Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proc Natl Acad Sci U S A (2007) 1.88
High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis (2008) 1.86
Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity (2008) 1.76
Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol (2006) 1.75
A prospective large-scale study of methods for the detection of latent Mycobacterium tuberculosis infection in refugee children. Thorax (2010) 1.70
Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS (2005) 1.55
Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J Virol (2006) 1.54
Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology (2009) 1.54
HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers. J Virol (2009) 1.54
Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut (2010) 1.53
Leveraging hierarchical population structure in discrete association studies. PLoS One (2007) 1.48
HIV/AIDS. HIV: experiencing the pressures of modern life. Science (2005) 1.45
Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology (2009) 1.44
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med (2011) 1.36
Interferon-induced thyroid dysfunction in chronic hepatitis C. J Gastroenterol Hepatol (2009) 1.36
Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica (2008) 1.33
Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls. PLoS Pathog (2013) 1.33
Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. J Virol (2012) 1.29
HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics (2012) 1.27
Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance. Clin Infect Dis (2005) 1.21
Mapping the landscape of host-pathogen coevolution: HLA class I binding and its relationship with evolutionary conservation in human and viral proteins. J Virol (2010) 1.17
Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs. J Immunol (2010) 1.15
Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences. Clin Infect Dis (2010) 1.13
Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol (2007) 1.12
Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir Ther (2004) 1.11
Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther (2003) 1.11
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica (2010) 1.08
Antiretroviral-therapy-associated lipoatrophy: current status and future directions. Sex Health (2005) 1.07
The development of PROQOL-HIV: an international instrument to assess the health-related quality of life of persons living with HIV/AIDS. J Acquir Immune Defic Syndr (2012) 1.07
Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? J HIV Ther (2003) 1.05
Unique features of HLA-mediated HIV evolution in a Mexican cohort: a comparative study. Retrovirology (2009) 1.04
T cell-mediated hypersensitivity reactions to drugs. Annu Rev Med (2014) 1.03
Extensive HLA-driven viral diversity following a narrow-source HIV-1 outbreak in rural China. Blood (2011) 1.01
Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther (2009) 1.00
Male breast ductal carcinoma in situ. ANZ J Surg (2003) 1.00
Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy. AIDS (2008) 0.99
Translation of HLA-HIV associations to the cellular level: HIV adapts to inflate CD8 T cell responses against Nef and HLA-adapted variant epitopes. J Immunol (2011) 0.98
Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes. J Biol Chem (2010) 0.97
HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. J Antimicrob Chemother (2007) 0.97
Key outcomes from stakeholder workshops at a symposium to inform the development of an Australian national plan for rare diseases. Orphanet J Rare Dis (2012) 0.97
Fatty acid oxidation products in human atherosclerotic plaque: an analysis of clinical and histopathological correlates. Atherosclerosis (2003) 0.97
Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. AIDS (2007) 0.96
Correction: Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis (2015) 0.96
High-avidity, high-IFNγ-producing CD8 T-cell responses following immune selection during HIV-1 infection. Immunol Cell Biol (2011) 0.96
HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection. Proc Natl Acad Sci U S A (2013) 0.96
Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study. J Clin Virol (2003) 0.96
Automation of the ELISpot assay for high-throughput detection of antigen-specific T-cell responses. J Immunol Methods (2009) 0.95
HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. Clin Infect Dis (2008) 0.95
Psychometric validation of the PROQOL-HIV questionnaire, a new health-related quality of life instrument-specific to HIV disease. J Acquir Immune Defic Syndr (2012) 0.95
Insulin resistance, dyslipidaemia, inflammation and endothelial function in nephrotic syndrome. Nephrol Dial Transplant (2002) 0.94
Identifying recombination hot spots in the HIV-1 genome. J Virol (2013) 0.93
Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity. J Virol (2012) 0.93
Multiple papillomas of the breast: is current management adequate? Breast (2006) 0.92
A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Pharmacogenet Genomics (2006) 0.91
Fifteen to twenty percent of HIV substitution mutations are associated with recombination. J Virol (2014) 0.91
Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS (2003) 0.91
Alleles of the KIR2DL4 receptor and their lack of association with pre-eclampsia. Eur J Immunol (2002) 0.89
Histologic analysis of liver tissue following hepatic arterial infusion of ferromagnetic particles in a rabbit tumour model. Biometals (2003) 0.89
HIV escape mutations occur preferentially at HLA-binding sites of CD8 T-cell epitopes. AIDS (2013) 0.88
Host-specific adaptation of HIV-1 subtype B in the Japanese population. J Virol (2014) 0.88
Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors. Am J Hum Genet (2003) 0.88
Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again. Pharmacogenomics (2006) 0.88
The structural basis of HLA-associated drug hypersensitivity syndromes. Immunol Rev (2012) 0.86
Constrained pattern of viral evolution in acute and early HCV infection limits viral plasticity. PLoS One (2011) 0.86
External quality assessment of HLA-B*5701 reporting: an international multicentre survey. Antivir Ther (2007) 0.86
Electronic versus paper-based assessment of health-related quality of life specific to HIV disease: reliability study of the PROQOL-HIV questionnaire. J Med Internet Res (2014) 0.86
The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome. J HIV Ther (2004) 0.85
Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert Opin Drug Saf (2005) 0.85